| Literature DB >> 29129301 |
Alain M Schoepfer1, Alex Straumann2, Ekaterina Safroneeva3.
Abstract
Eosinophilic esophagitis (EoE) is defined as a chronic, immune-medicated or antigen-mediated, esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Food allergens are identified in most patients. Treatment strategies include elimination diets, drugs, and esophageal dilation. This article focuses on pharmacologic treatment. Currently, there is no pharmacologic treatment that has been approved by regulatory authorities. Established pharmacologic options to treat EoE include proton pump inhibitors and swallowed topical steroids. Several biologic therapies are currently under evaluation and some of them have shown promising results in improving biologic endpoints and patient-reported outcomes.Entities:
Keywords: Biologic therapy; Budesonide; Eosinophilic esophagitis; Fluticasone; Pharmacologic treatment; Proton pump inhibitors
Mesh:
Substances:
Year: 2017 PMID: 29129301 DOI: 10.1016/j.giec.2017.07.007
Source DB: PubMed Journal: Gastrointest Endosc Clin N Am ISSN: 1052-5157